Probucol in Alzheimer's disease Study (PIA-Study)
Welcome to the Probucol in Alzheimer's disease Study
A clinical trial to examine the impact of a potential new treatment (Probucol) on memory and thinking skills in people with Alzheimer's disease.
About the Clinical Trial
The Probucol in Alzheimer's disease Study (PIA-Study) is based on research led by Professor John Mamo at the Western Australia-based Curtin Health Innovation Research Institute, Curtin University. Professor Mamo's team has uncovered compelling evidence that a build-up of molecules in the blood cause damage to brain capillaries, which may be associated with Alzheimer's disease.
The team has also identified a potential new treatment that may suppress the production and leakage of these small molecules into the blood, protect brain capillaries and improve memory and cognitive function.
With funding support from the Australian Government's Medical Research Future Fund 2020 ($1.72 million) and MSWA ($550,000), the team has now progressed its studies of Probucol to a clinical trial, moving closer towards its goal of developing a new treatment for Alzheimer's disease.
The clinical trial is being conducted in Perth, WA, starting in 2021.
Who We Are
We are a multi-disciplinary collaborative team of researchers, clinicians and other health professionals running a clinical trial of the drug Probucol as a potential new treatment for Alzheimer's disease. The clinical trial is run at the Australian Alzheimer's Research Foundation (AARF) and sponsored by Curtin University.
